Sarto - A patch has to be on the agenda targeting both systemic and non-systemic delivery - the benefit of providing a steady therapeutic dose.
Eventually novartis must be aware that Voltaren tablets, which has significant adverse effects with prolonged use, has to be under threat by a TPM boosted Diclofenac patch.
So much potential - the first step up the ladder has been taken - as JM suggests - we might be climbing the next few a bit quicker than it did to climb the first.
novartis signs up poh's tpm, page-9
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 36084472 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 35403846 | 21 |
View Market Depth
| Last trade - 16.12pm 11/10/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable